Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

The main purpose of this study is to find out whether inobrodib, when given with pomalidomide and dexamethasone, works better than standard treatment for people whose multiple myeloma has come back or has not improved after previous treatment. The study will look at how long people taking part in the study ("Participants") live without their myeloma getting worse, and how many people's myeloma improves (responds) following treatment. The study will also look at how long participants live overall, how quickly treatment works, how long the response lasts, whether very small amounts of myeloma c

Trial Details

NCT ID
NCT07772024
Phase
PHASE3
Sponsor
CellCentric Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • InoPd
  • Investigator's choice of SAT
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Adults aged 18 years or older (or the minimum age of consent under local rules, if that is 18 or over)
  • A diagnosis of multiple myeloma that has either come back (relapsed) or did not respond (refractory) after the most recent treatment
  • Myeloma that can be measured using standard study tests (blood and/or urine tests)
  • Between 1 and 4 previous courses (lines) of myeloma treatment, which must have included both a treatment that targets CD38 (such as daratumumab or …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →